Category: Portfolio News

March 1, 2017

Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study

Learn More-External LinkRead the Full Article

February 28, 2017

Opsens Announces Graduation to TSX

QUEBEC CITY, Feb. 28, 2017 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has received final approval for the listing of the Corporation's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX"). The Common Shares will commence trading on...Read the Full Article

January 25, 2017

BAROnova Announces Completion of ENDObesity® II Pivotal Clinical Trial Enrollment

SAN CARLOS, Calif., Jan. 25, 2017 /PRNewswire/ -- BAROnova, Inc., announced completion of its randomized cohort enrollment in the ENDObesity II Study, a multicenter randomized pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle® (TPS®), which treats obesity. Richard Rothstein, MD, the lead investigator of the study...Read the Full Article

January 24, 2017

Exact Imaging artcle in Medical Device Daily

Learn More-External LinkRead the Full Article

January 9, 2017

Celtaxsys Welcomes New Board Member Abel De La Rosa

Atlanta, GA. – Celtaxsys, a clinical stage pharmaceutical development company focused on advancing novel anti-inflammatory treatment for rare and orphan diseases, announced today the appointment of Dr. Abel De La Rosa to the company board of directors. He currently serves as Chief Scientific Officer for the Drug Innovations Venture at Emory (DRIVE)...Read the Full Article

January 5, 2017

Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration

January 05, 2017 05:00 AM Eastern Standard Time VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced the successful achievement of a research milestone in a second immune-modulating bispecific antibody in...Read the Full Article

January 5, 2017

Exact Imaging secures CDN $21.5 Million in financing to support the commercialization of its new disruptive ExactVu™ micro-ultrasound for prostate imaging and biopsy

TORONTO, Jan. 5, 2017 /PRNewswire/ - Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has secured CDN $21.5 million in a Series C investment to commercialize its ExactVu™ micro-ultrasound system. The financing, which closed late in 2016, was...Read the Full Article

Scroll to Top